1. The latest news: Merck’s Keytruda blockbuster potential in China — Spectrum pulls marketing app for Neulasta rival — Genfit seeks $132M IPO for NASH programs -- See more on our front page news

    Plus this week’s message board spotlight: Therapeutic Specialties boards
    Dismiss Notice
  2. Dealing with a potential legal issue at work?Ask an Employment Attorney -- a chance to discuss employment-related legal issues with a practicing attorney with over 20 years in employment law experience.
    Dismiss Notice

Cost cuts are coming for Allergan, CEO Brent Saunders says

Discussion in 'Allergan' started by anonymous, Nov 3, 2017 at 5:42 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    time to get out!
     
  2. anonymous

    anonymous Guest

    Heading into Allergan’s third-quarter conference call, executives knew investors were skittish about the prospect of Restasis generics. So they spelled out their solution loud and clear: Cost cuts are coming, and “rapidly.”

    Executives are currently sifting through the details of cost-squeezing proposals they drew up earlier this year, CEO Brent Saunders said on the call. And considering Allergan’s experience wringing savings out of its many M&A deals, investors shouldn’t worry. When it was Actavis, the company slashed 577 jobs at its Irvine, CA headquarters alone as part of the $1.8 billion in savings it plotted when it took over Allergan.

    “This team is up for it,” Saunders said. “I hate to say we know how to take costs out of the business, but we do, and we know how to do that in a way that protects the long-term growth drivers.”
     
  3. anonymous

    anonymous Guest

    “This team is up for it,” Saunders said. “I hate to say we know how to take costs out of the business, but we do, and we know how to do that in a way that protects the long-term growth drivers.”
     
  4. anonymous

    anonymous Guest

    Saunders is a sad joke of a CEO
     
  5. anonymous

    anonymous Guest



    Saunders needs to be shown the door!
     
  6. anonymous

    anonymous Guest

  7. ALLERGAN ANNOUNCES MAJOR COST SAVINGS FROM FACIAL HAIR PROGRAM

    Allergan has reported $173 Million dollars in savings from the Facial Hair Extension Program. By encouraging employees to grow scraggly unkept beards, mustaches, or morning shadow, Allergan has reduced spending on free razors while simultaneous reducing the health care spending associated with the treatment of shaving induced cuts. "We expect this bold initiative to allow us to generate significant cost savings across the enterprise" said Brent "Marlboro Man" Saunders CEO of Allergan "We expect to lower heating bills as the hair keeps employees warm and to extend our savings by encouraging employees to grow luxurious hair under their arms and on their legs as well". Allergan is currently the global leader in the "Grow More Hair" movement. Analysts estimate that with the inclusion of the underarm and leg extensions and the associated reductions in building heating costs that annual savings may exceed $1 Billion. Allergan has committed to redeploy any savings from the program to expanded outplacement support for future ex-employees.
     
  8. anonymous

    anonymous Guest

    ROFL!!!
     
  9. anonymous

    anonymous Guest

    too many overpaid sales reps hanging out at the gym or getting injections in their puffy faces. Anybody actually work? Cut the fat and. Post that dropping stock
     
  10. anonymous

    anonymous Guest

    BS never said a reduction in the field sales force. This is a group he has always valued and understands the importance of since he became a leader. Cuts will not come here
     
  11. anonymous

    anonymous Guest

    Uhhh.....they just cut the field sales force by 200+ reps. And that was before losing restasis.
     
  12. anonymous

    anonymous Guest

    Right. Because no sales reps were laid off on the last 3 reorganizations, right?

    Are you stoned, drunk or stupid? It's a legit question.
     
  13. anonymous

    anonymous Guest

    Restasis is a blockbuster. Not in that division but BS will protect that product and sales force till the end.
     
  14. anonymous

    anonymous Guest

    Do you think women’s health reps will be safe?
     
  15. anonymous

    anonymous Guest

    I don't think that anyone is safe! If they are trying to cut costs to compensate for a billion dollar product, I predict across the board cuts.
     
  16. anonymous

    anonymous Guest

    My prediction is any people displaced will be realigned to the Restasis initiative. Restasis is BSs pet. He will increase voice level to squeeze every penny out of it. That is why he has been so successful. Just thoughts.
     
  17. anonymous

    anonymous Guest

    Do these layoffs pertain to the aesthetic division or just primary care reps? I am in the process of interviewing for BDM position...
     
  18. anonymous

    anonymous Guest

    Restasis is Brent's pet? This is laughable.

    He had nothing to do with formulation it, nothing to do with designing the clinical studies (no easy task I might add for a dry eye product), nothing to do with getting FDA approval (very difficult task for this first in class drug), etc. Nothing to do with writing the most recent 6 patents on it. Seriously, nothing to do with it at all in any regard.

    He may love the product. It is a top seller but he certainly shouldn't get credit for the success of Restasis. Restasis was successful due to the efforts of Allergan's former R&D team long before Brent was on the scene.
     
  19. anonymous

    anonymous Guest

    Welcome to 2017! And the reality that someone else with Big Words “BOLD” and fake euphoniums “Growth Pharma” stole your concepts and your company. The saddest thing to me is that they get away with it and are handsomely rewarded. Welcome to the middle class; Brent Saunders and the board at AGN hear you, NOT and care about your
    Contribution. Sweet Dreams
     
  20. anonymous

    anonymous Guest

    All. Facial has way too many BDM’s, managers and directors. Our APC’s aren’t worth anything. We should start there. Train the bdms to do the same benchmarking reports.
     



play:inline;">